Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Bemiltenase alfa in Hemophilia: NCT05027230 Clinical Landscape Report 2026
16 October 2026
NCT05027230 clinical landscape for Hemophilia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Withania somnifera Extract in Amyotrophic Lateral Sclerosis: NCT05031351 Clinical Landscape Report 2026
16 October 2026
NCT05031351 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rivaroxaban in Upper Extremity Deep Vein Thrombosis: NCT05033314 Clinical Landscape Report 2026
16 October 2026
NCT05033314 clinical landscape for Upper Extremity Deep Vein Thrombosis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Fipaxalparant in Idiopathic Pulmonary Fibrosis: NCT05032066 Clinical Landscape Report 2026
16 October 2026
NCT05032066 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Damoctocog Alfa Pegol in Hemorrhage: NCT05036278 Clinical Landscape Report 2026
16 October 2026
NCT05036278 clinical landscape for Hemorrhage: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Osivelotor in Anemia, Sickle Cell: NCT05036512 Clinical Landscape Report 2026
16 October 2026
NCT05036512 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efruxifermin in Fibrosis, Liver: NCT05039450 Clinical Landscape Report 2026
16 October 2026
NCT05039450 clinical landscape for Fibrosis, Liver: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NI-005 in Amyotrophic Lateral Sclerosis: NCT05039099 Clinical Landscape Report 2026
16 October 2026
NCT05039099 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TB-840 in Metabolic Dysfunction Associated Steatohepatitis: NCT05045534 Clinical Landscape Report 2026
16 October 2026
NCT05045534 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
3K3A-APC in Amyotrophic Lateral Sclerosis 4, Juvenile: NCT05039268 Clinical Landscape Report 2026
16 October 2026
NCT05039268 clinical landscape for Amyotrophic Lateral Sclerosis 4, Juvenile: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Letermovir in Idiopathic Pulmonary Fibrosis: NCT05041426 Clinical Landscape Report 2026
16 October 2026
NCT05041426 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rurioctocog alfa pegol in Hemophilia A: NCT05042440 Clinical Landscape Report 2026
16 October 2026
NCT05042440 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.